What is Hims & Hers Health (HIMS) Stock?
Hims & Hers Health, Inc. (NYSE: HIMS) is a telehealth company founded in 2017 that provides prescription medications, over-the-counter products, and personal care solutions through a direct-to-consumer model. The company’s offerings include treatments for mental health, sexual health, dermatology, and weight loss.
In January 2021, Hims & Hers went public via a SPAC merger with Oaktree Capital Management at a valuation of $1.6 billion. The company has since expanded its portfolio to include compounded GLP-1 injections for weight loss and partnerships with pharmaceutical giants like Eli Lilly.
Key Developments in 2025
- February 21: Hims & Hers acquires a U.S.-based peptide facility in California to strengthen its supply chain for personalized medications.
- March 25: HIMS stock rises 5% to $29.46 following strong quarterly performance and optimistic revenue guidance for 2025.
- April 1: The company announces it will sell Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro on its platform. Shares jump 5.1% on the news.
- April 2: Analysts highlight Hims & Hers’ potential as a leader in telehealth innovation despite regulatory challenges surrounding compounded GLP-1 drugs.
Stock Performance and Financial Highlights
As of April 2025, HIMS is trading at $31.31 per share, up 24.4% year-to-date but still 54.5% below its 52-week high of $68.74 in February. The company projects $2.3 billion in revenue for 2025, with $725 million expected from its weight-loss segment alone.
- Revenue Growth: $1.48 billion in 2024 (up 69% YoY).
- Profitability: Net income of $126 million in 2024 compared to a net loss of $25 million in 2023.
- Adjusted EBITDA: Projected at $270–$320 million for 2025.
- Cash Reserves: Strong cash-to-assets ratio of 42.2%, ensuring financial stability.
Recent Challenges and Opportunities
The FDA’s decision to end the shortage designation for semaglutide (the active ingredient in Wegovy and Ozempic) has raised concerns about the future of compounded GLP-1 drugs offered by Hims & Hers. However, the company plans to pivot toward oral-based solutions and branded alternatives like liraglutide to sustain growth in its weight-loss segment.
The acquisition of Trybe Labs further positions Hims & Hers as a leader in personalized healthcare by enabling at-home lab testing services for conditions like low testosterone and menopause support.
The Road Ahead
Hims & Hers is betting big on telehealth innovation by integrating advanced technologies and expanding its product portfolio. CEO Andrew Dudum envisions the platform as the “next-generation healthcare solution,” combining personalization with affordability and accessibility.
The company’s ability to navigate regulatory hurdles while maintaining strong revenue growth will be critical to its long-term success. Investors remain optimistic about its potential despite short-term volatility.